Portal offers pay-per-use ADME services

Drug discovery technology and information company Cyprotex has launched Cloe Gateway, a web portal for access to drug discovery services. The services are available on a pay-per-use basis.

The portal is an enhanced version of the company's proprietary software, Cloe PK, which predicts whole body pharmacokinetics from simple in vitro absorption, distribution, metabolism and excretion (ADME) and physicochemical properties. According to an announcement, the portal lets researchers gain additional insight from ADME data in the form of pharmacokinetic performance characteristics.

"The cost effectiveness of this approach will allow new audiences of scientists, such as bench medicinal chemists, to access these predictive technologies," says Anthony D. Baxter, the company's CEO, in an announcement. "This approach to selling software solutions is new to the ADME / pharmacokinetic world and we anticipate it will grow to replace competitor products still being sold on the outdated server/license model."

Cyprotex says it plans to make additional products available via the portal, including a human intestinal absorption model, and provide access to its Cloe Screen ADME screening service.

- read the Cyprotex release

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.